{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-212168","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.738939+00:00","generated_at":"2026-05-31T06:37:38.644845+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atara raises ~$36M via registered direct offering; appoints Gregory Ciongoli to board","bullets":["Registered direct offering of 758,900 shares and pre-funded warrants for up to 3,604,780 shares at $8.25/$8.2499.","Gross proceeds ~$36M; net proceeds for working capital and general corporate purposes.","Adiumentum Capital Fund I LP (Ciongoli is Managing Partner) purchases $7.5M of the offering.","Gregory A. Ciongoli appointed to Board of Directors effective upon closing on September 5, 2024.","Ciongoli is independent, not receiving director compensation; standard indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-212168","json":"https://secwatch.observer/filing/0001193125-24-212168.json","markdown":"https://secwatch.observer/filing/0001193125-24-212168.md","text":"https://secwatch.observer/filing/0001193125-24-212168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524212168/0001193125-24-212168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524212168/d852765d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:37:38.644845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92aaaed44d","claim":"Gregory A. Ciongoli was appointed as member of the Board at Atara Biotherapeutics, Inc..","evidence_excerpt":"On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524212168/0001193125-24-212168-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}